The North America point of care diagnostics market exhibits consistent growth from 2020 through 2035. In 2025, total market revenue is projected to reach 7,350 Million, up from 5,800 Million in 2021, with a sustained CAGR through the forecast period. Growth is underpinned by accelerating adoption of POCT in both clinical and non-clinical settings, improved accessibility, and continuous innovation by leading players. The forecast suggests that by 2035, revenue will surpass 15,200 Million as penetration into home and retail healthcare accelerates alongside advancements in digital health integration.

Read More - https://bussinessinsights.com/research-report/north-america-point-of-care-diagnostics-market

Diabetes and infectious disease applications remain at the forefront of point of care diagnostics adoption in North America for 2025. Diabetes commands the largest single share, driven by consumer uptake of self-monitoring solutions and an aging population. Infectious disease testing follows closely, with a pronounced need for rapid virus, bacteria, and pathogen identification in ambulatory and emergency care. Cardiology, oncology, and drug abuse testing continue to show incremental growth as POCT capabilities expand, allowing clinicians to react swiftly to a diverse range of urgent healthcare needs.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-point-of-care-diagnostics-market

Frequently Asked Questions

Who are the key players in North America Point of Care Diagnostics Market industry?
The key players in the North America Point of Care Diagnostics Market include Abbott Laboratories, Roche Diagnostics, Danaher Corporation, BD (Becton, Dickinson and Company), and Siemens Healthineers. These companies are recognized for their innovations, extensive product portfolios, and strategic collaborations that help expand access to rapid diagnostic solutions across the region.

What is the North America Point of Care Diagnostics Market growth?
The North America Point of Care Diagnostics Market is experiencing significant growth, driven by increasing demand for rapid tests. Companies like Abbott reported a strong rise in sales for their rapid COVID-19 tests in 2023, and the market is projected to grow at a CAGR of over 7% during 2024-2028.

Which segment accounted for the largest North America Point of Care Diagnostics Market share?
The infectious disease testing segment held the largest share of the North America Point of Care Diagnostics Market, primarily due to high demand for influenza, COVID-19, and HIV tests. Rapid and accurate results in hospital, clinic, and home care settings have accelerated its adoption throughout North America.

Thanks & Regards,
Priya
sales@bussinessinsights.com